PPT-Switching from TDF/FTC to TAF/

FTC Study 3111089 Switching from TDFFTC to TAF FTC Study 311 Design Source Gallant JE et al Lancet HIV 20163e15865 Switch to TAFFTC n 333 Continue TDFFTC n 330 Patients on a pharmacokinetic booster ritonavir received tenofovir alafenamideemtricitabine 10200 mg. ZDV/3TC . vs. TDF + FTC. Study 934. ABC/3TC . vs. TDF/FTC. HEAT Study. ACTG A5202 Study. ASSERT Study. FTC/TDF vs FTC/TAF. Studies GS-US-292-0104 and GS-US-292-0111. GS-US-292-0104/0111. Design. Objective. STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (mITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -12%, 85% power. If non-inferiority and lower margin > 0, assessment for superiority. Brian R. Wood, MD. Assistant Professor of Medicine, University of Washington. Medical Director, Frontier AETC ECHO. October 2015. ID Week Review 2015. 1) Switching from TDF to TAF. 2) Simplifying salvage therapy to E/C/F/TAF + DRV. Massachusetts General Hospital. Boston, Massachusetts. State-of-the-ART in Antiretroviral Therapy: Optimal Initial Regimens in 2016. Washington, DC: August 23, 2016. Thanks to Alice Pau, Roger Bedimo and Marilyn Shi for assistance with slides. Estudio GS-US-311-1089 . Estudio GS-US-366-1216 . Estudio GS-US-366-1160 . . Diseño. Endpoints. Primario: proporción de pacientes . con C. V . < 50 c/mL a S48 (ITT, . snapshot. ) ; no inferioridad si el margen inferior de IC95% de dos colas para la diferencia = - 8%, poder 85%. Treating and Preventing HIV in 2019: Interactive Cases From the Clinic(ians) Michael S. Saag , MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials Andrew Hill, Francois Venter, Eric Delaporte , Simiso Sokhela, Charles amoe@mednet.ucla.edu. UCLA CARE clinic/NEVHC Van Nuys . 21 June 2014. I do not have any financial arrangements or affiliations with commercial sponsors which have direct interest in the subject matter. Medical Director, Specialty . Services. Southwest CARE Center. Santa Fe, New Mexico. State-of-the-ART. . in . Antiretroviral . Management. FORMATTED: MM/DD/YY. New Orleans, Louisiana: December 15-17, 2015. in a Single-Tablet Regimen . in Initial HIV-1 Therapy. Combined Primary Results of . Studies GS-US-292-0104 and GS-US-292-0111. David Wohl. 1. , Anton Pozniak. 2. , Melanie Thompson. 3. , Edwin DeJesus. Study 1249. Elvitegravir-Cobicistat-TAF-FTC in HIV/HBV Coinfection . Study 1249: . Design. Source: Gallant J, et al. . J. . Acquir. Immune . Defic. . Syndr. . 2016;73:294-8.. Baseline ART. (n = 72). and . Virologic. Outcomes . for Treatment-experienced . People Living with HIV Switching to MTR or STR ART since 2018 . Ben Chastek. 1. , Amy Anderson. 1. , Joshua Gruber. 2. , Sunil Majethia. 2. , Woodie Zachry. Study 105. Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2). Study 105: Study Design. Source: . Elion. R, et al. AIDS. 2011;25:1881-6. . Background. : Randomized, partially placebo-controlled, double-blind phase 2 trial to compare the safety and efficacy of cobicistat and ritonavir as pharmacokinetic enhancers administered with atazanavir and fixed-dose tenofovir DF-emtricitabine in treatment-naïve adults with HIV infection. RADAR Trial. Raltegravir. + Darunavir/r versus TDF-FTC + Darunavir/r. RADAR: Study Design. Source: . Bedimo. RJ, et al. . PLoS. One. 2014;9:e106221.. Darunavir QD + Ritonavir QD + Raltegravir BID .